Apalutamide for metastatic, castration-sensitive prostate cancer
Background Apalutamide is an inhibitor of the ligand-binding domain of the androgen
receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would …
receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would …
Re: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
SS Taneja - Journal of Urology, 2019 - journals.lww.com
In this report of TITAN (A Study of Apalutamide plus ADT versus ADT in Participants with
mHSPC) men with castration sensitive metastatic prostate cancer were randomized to …
mHSPC) men with castration sensitive metastatic prostate cancer were randomized to …
Apalutamide for metastatic, castration-sensitive prostate cancer
KN Chi, N Agarwal, A Bjartell… - … England Journal of …, 2019 - yonsei.elsevierpure.com
BACKGROUND Apalutamide is an inhibitor of the ligand-binding domain of the androgen
receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would …
receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would …
Apalutamide for metastatic, castration-sensitive prostate cancer
KN Chi, N Agarwal, A Bjartell… - … England Journal of …, 2019 - research.uni-luebeck.de
BACKGROUND Apalutamide is an inhibitor of the ligand-binding domain of the androgen
receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would …
receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would …
[引用][C] Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
KN Chi, N Agarwal, A Bjartell, BH Chung… - New England Journal …, 2019 - cir.nii.ac.jp
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer | CiNii Research CiNii 国立
情報学研究所 学術情報ナビゲ恁縖サイニィ] 詳細へ移動 検索フォ恁啶匾動 論文·デ恁郡颏丹す …
情報学研究所 学術情報ナビゲ恁縖サイニィ] 詳細へ移動 検索フォ恁啶匾動 論文·デ恁郡颏丹す …
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
KN Chi, N Agarwal, A Bjartell… - … England Journal of …, 2019 - portal.research.lu.se
BACKGROUND: Apalutamide is an inhibitor of the ligand-binding domain of the androgen
receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would …
receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would …
Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
KN Chi, N Agarwal, A Bjartell, BH Chung… - 2019 - ir.ymlib.yonsei.ac.kr
BACKGROUND: Apalutamide is an inhibitor of the ligand-binding domain of the androgen
receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would …
receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would …
[PDF][PDF] Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
KN Chi, N Agarwal, A Bjartell, BH Chung… - 2019 - researchgate.net
BACKGROUND Apalutamide is an inhibitor of the ligand-binding domain of the androgen
receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would …
receptor. Whether the addition of apalutamide to androgen-deprivation therapy (ADT) would …
[引用][C] Re: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer
SS Taneja - The Journal of urology, 2019 - nyuscholars.nyu.edu
Re: Apalutamide for Metastatic, Castration-Sensitive Prostate Cancer — NYU Scholars Skip to
main navigation Skip to search Skip to main content NYU Scholars Home NYU Scholars Logo Help …
main navigation Skip to search Skip to main content NYU Scholars Home NYU Scholars Logo Help …
Apalutamide for metastatic, castration-sensitive prostate cancer
KN Chi, N Agarwal, A Bjartell, BH Chung… - NEW ENGLAND …, 2019 - iris.uniroma1.it
Apalutamide is an inhibitor of the ligand-binding domain of the androgen receptor. Whether
the addition of apalutamide to androgen-deprivation therapy (ADT) would prolong …
the addition of apalutamide to androgen-deprivation therapy (ADT) would prolong …